Bertrand J Jean-Claude
Overview
Explore the profile of Bertrand J Jean-Claude including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
310
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chaddad A, Kucharczyk M, Daniel P, Sabri S, Jean-Claude B, Niazi T, et al.
Front Oncol
. 2019 Jun;
9:374.
PMID: 31165039
Radiomics analysis has had remarkable progress along with advances in medical imaging, most notability in central nervous system malignancies. Radiomics refers to the extraction of a large number of quantitative...
12.
Rupp M, Mouhri Z, Williams C, Jean-Claude B
Oncotarget
. 2018 Nov;
9(80):35041-35055.
PMID: 30416678
Disordered expression of the epidermal growth factor receptor (EGFR) has been associated with induction of DNA repair genes (e.g. XRCC1, ERCC1) and resistance to radiation and genotoxic drugs. However, our...
13.
Mouhri Z, Goodfellow E, Kelley S, Stein R, Rogers R, Jean-Claude B
Molecules
. 2017 Jul;
22(7).
PMID: 28753938
6-(3-Methyltriaz-1-en-1-yl)-1-benzo[de]isoquinoline-1,3(2)-dione referred to as EG22 (), is an open-chain 3-alkyl-1,2,3-triazene termed "combi-molecule" designed to inhibit poly(adenosine diphosphate ribose) polymerase (PARP) and damage DNA. To delay its hydrolysis, acetylation of N3...
14.
Goodfellow E, Mouhri Z, Williams C, Jean-Claude B
Bioorg Med Chem Lett
. 2016 Dec;
27(3):688-694.
PMID: 28003142
In order to enhance the cytotoxic potential of poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1 or 2 deficient tumours, we designed a series of molecules containing a 1,2,3-triazene moiety tethered to...
15.
Heravi M, Kumala S, Rachid Z, Jean-Claude B, Radzioch D, Muanza T
Int J Radiat Oncol Biol Phys
. 2015 Apr;
92(2):399-406.
PMID: 25823448
Purpose: ZRBA1 is a combi-molecule designed to induce DNA alkylating lesions and to block epidermal growth factor receptor (EGFR) TK domain. Inasmuch as ZRBA1 downregulates the EGFR TK-mediated antisurvival signaling...
16.
Rao S, Larroque-Lombard A, Peyrard L, Thauvin C, Rachid Z, Williams C, et al.
PLoS One
. 2015 Feb;
10(2):e0117215.
PMID: 25658745
Cancer cells are characterized by a complex network of interrelated and compensatory signaling driven by multiple kinases that reduce their sensitivity to targeted therapy. Therefore, strategies directed at inhibiting two...
17.
Huang Y, Rachid Z, Peyrard L, Mouhri Z, Williams C, Jean-Claude B
Chem Biol Drug Des
. 2014 Aug;
85(2):153-62.
PMID: 25092264
To potentiate the quinazoline-based inhibitor of the epidermal growth factor receptor (EGFR), a chloroethyl alkylating moiety was appended to its 6-position. This led to molecules with extremely strong EGFR inhibitory...
18.
Ait-Tihyaty M, Rachid Z, Larroque-Lombard A, Jean-Claude B
Invest New Drugs
. 2013 Aug;
31(6):1409-23.
PMID: 23959266
Capecitabine, an orally available prodrug of 5-FU, requires activation by carboxylesterase (CES) enzymes present in the liver to generate 5'-deoxy-5-flurocytidine ribose (5'-DFCR). The deamination of the latter by cytidine deaminase...
19.
Larroque-Lombard A, Ning N, Rao S, Lauwagie S, Halaoui R, Coudray L, et al.
Chem Biol Drug Des
. 2012 Sep;
80(6):981-91.
PMID: 22943437
In breast cancer cells expressing c-Src and EGFR, a control of one of the two oncogenes over proliferation and invasion is observed, whereas in others, the synergistic interaction between them...
20.
Watt H, Rachid Z, Jean-Claude B
J Signal Transduct
. 2012 Apr;
2012:282050.
PMID: 22523681
Recently, we reported the combination of multitargeted ErbB1 inhibitor-DNA damage combi-molecules with OCT in order to downregulate ErbB1 and activate SSTRs. Absence of translation to cell kill was believed to...